» Articles » PMID: 31837825

Modulating Neuroinflammation and Oxidative Stress to Prevent Epilepsy and Improve Outcomes After Traumatic Brain Injury

Overview
Specialties Neurology
Pharmacology
Date 2019 Dec 16
PMID 31837825
Citations 51
Authors
Affiliations
Soon will be listed here.
Abstract

Traumatic brain injury (TBI) is a leading cause of death and disability in young adults worldwide. TBI survival is associated with persistent neuropsychiatric and neurological impairments, including posttraumatic epilepsy (PTE). To date, no pharmaceutical treatment has been found to prevent PTE or ameliorate neurological/neuropsychiatric deficits after TBI. Brain trauma results in immediate mechanical damage to brain cells and blood vessels that may never be fully restored given the limited regenerative capacity of brain tissue. This primary insult unleashes cascades of events, prominently including neuroinflammation and massive oxidative stress that evolve over time, expanding the brain injury, but also clearing cellular debris and establishing homeostasis in the region of damage. Accumulating evidence suggests that oxidative stress and neuroinflammatory sequelae of TBI contribute to posttraumatic epileptogenesis. This review will focus on possible roles of reactive oxygen species (ROS), their interactions with neuroinflammation in posttraumatic epileptogenesis, and emerging therapeutic strategies after TBI. We propose that inhibitors of the professional ROS-generating enzymes, the NADPH oxygenases and myeloperoxidase alone, or combined with selective inhibition of cyclooxygenase mediated signaling may have promise for the treatment or prevention of PTE and other sequelae of TBI. This article is part of the special issue entitled 'New Epilepsy Therapies for the 21st Century - From Antiseizure Drugs to Prevention, Modification and Cure of Epilepsy'.

Citing Articles

Total Antioxidant Status in Critically Ill Patients with Traumatic Brain Injury and Secondary Organ Failure-A Systematic Review.

Rynkiewicz-Szczepanska E, Kosciuczuk U, Maciejczyk M Diagnostics (Basel). 2024; 14(22).

PMID: 39594227 PMC: 11593164. DOI: 10.3390/diagnostics14222561.


Oxidative Stress in the Murine Model of Extraparenchymal Neurocysticercosis.

Generoso D, Martins T, Camacho C, Segredo M, Batah S, Fabro A Microorganisms. 2024; 12(9).

PMID: 39338534 PMC: 11433719. DOI: 10.3390/microorganisms12091860.


High-dimensional proteomic analysis for pathophysiological classification of traumatic brain injury.

Li L, Kodosaki E, Heslegrave A, Zetterberg H, Graham N, Zimmerman K Brain. 2024; 148(3):1015-1030.

PMID: 39323289 PMC: 11884744. DOI: 10.1093/brain/awae305.


Vitamin D Relieves Epilepsy Symptoms and Neuroinflammation in Juvenile Mice by Activating the mTOR Signaling Pathway via RAF1: Insights from Network Pharmacology and Molecular Docking Studies.

Lu T, Chen X, Zhang Q, Shang K, Yang X, Xiang W Neurochem Res. 2024; 49(9):2379-2392.

PMID: 38837094 DOI: 10.1007/s11064-024-04176-y.


Valproic Acid Treatment after Traumatic Brain Injury in Mice Alleviates Neuronal Death and Inflammation in Association with Increased Plasma Lysophosphatidylcholines.

Hummel R, Dorochow E, Zander S, Ritter K, Hahnefeld L, Gurke R Cells. 2024; 13(9.

PMID: 38727269 PMC: 11083124. DOI: 10.3390/cells13090734.


References
1.
Ma M, Wang J, Zhang Q, Wang R, Dhandapani K, Vadlamudi R . NADPH oxidase in brain injury and neurodegenerative disorders. Mol Neurodegener. 2017; 12(1):7. PMC: 5240251. DOI: 10.1186/s13024-017-0150-7. View

2.
Zhang L, Liu J, Cheng C, Yuan Y, Yu B, Shen A . The neuroprotective effect of pyrroloquinoline quinone on traumatic brain injury. J Neurotrauma. 2011; 29(5):851-64. PMC: 3303106. DOI: 10.1089/neu.2011.1882. View

3.
Schiavone S, Sorce S, Dubois-Dauphin M, Jaquet V, Colaianna M, Zotti M . Involvement of NOX2 in the development of behavioral and pathologic alterations in isolated rats. Biol Psychiatry. 2009; 66(4):384-92. DOI: 10.1016/j.biopsych.2009.04.033. View

4.
Eyo U, Murugan M, Wu L . Microglia-Neuron Communication in Epilepsy. Glia. 2016; 65(1):5-18. PMC: 5116010. DOI: 10.1002/glia.23006. View

5.
Ravizza T, Terrone G, Salamone A, Frigerio F, Balosso S, Antoine D . High Mobility Group Box 1 is a novel pathogenic factor and a mechanistic biomarker for epilepsy. Brain Behav Immun. 2017; 72:14-21. DOI: 10.1016/j.bbi.2017.10.008. View